changing clinical trial endpoints in mpns & the link between hematopoietic fitness and outcomes
Published 1 year ago • 59 plays • Length 3:50Download video MP4
Download video MP3
Similar videos
-
1:54
a novel clinical trial endpoint for acute gvhd
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
1:00
how genomic testing has influenced treatment approaches and clinical trial design in mpns
-
1:31
mrd as an endpoint in clinical trials
-
1:51
checkpoint inhibition in the treatment of mpns
-
3:48
trials of interest in newly diagnosed myeloma presented at ims 2024
-
1:40
the importance of measuring qol outcomes in cll clinical trials
-
11:11
lecture medical oncology - endpoints in clinical trials
-
33:17
cpt pathology and laboratory guidelines
-
7:38
clinical research study start up regulatory documents explained quickly!
-
21:14
clinical interpretation and validity of clinical trials: when do they become practice changing?
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
4:36
impact: a uk clinical trials programme for hemonc patients post-transplant
-
1:56
ongoing and future trials in mpn-ap/bp
-
15:45
updates on the use of ropeginterferon in the treatment of mpns
-
0:15
transforming clinical trial operations: the next big step
-
1:12
the reduced prognostic impact of the cll-ipi in the new era of targeted agents
-
1:25
prognostic and predictive biomarkers in cll and their potential in guiding treatment decisions
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
1:42
the future of cll treatment: aiming for long-lasting remission
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl